The patient courses will include the three-month 3HP regimen, and the even shorter 1HP, that is only taken for 28 days. This contribution is part of the Consortium’s ongoing efforts to end TB and improve global health outcomes.
The launch of the study coincides with the World TB week. “Titled `PraGaTHi’, this study will explore how the changes in immunity due to pregnancy and GDM increase the risk of TB in pregnant and postpartum women.”